Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
University College Cork
Cedars-Sinai Medical Center
Baylor College of Medicine
Cancer Research UK
University of Miami
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Brown University
VA Office of Research and Development
Centre Hospitalier Régional d'Orléans
CellCentric Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Weill Medical College of Cornell University
Northwestern University
Memorial Sloan Kettering Cancer Center
Indapta Therapeutics, INC.
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Pack Health
Hangzhou Sumgen Biotech Co., Ltd.
Ciusss de L'Est de l'Île de Montréal
Baylor College of Medicine
Ohio State University Comprehensive Cancer Center
The Third Affiliated Hospital of Southern Medical University
National Institutes of Health Clinical Center (CC)
Ciusss de L'Est de l'Île de Montréal